Our August 2016 presenting company was KIYATEC out of Greenville, South Carolina.

KIYATEC is ushering in a new world of cancer drug response profiling that use living cells grown and tested in a more relevant 3D tumor microenvironment.  They are dedicated to changing how the pharmaceutical industry and clinicians evaluate, test and deliver innovative cancer therapeutics.

Over eight meetings in seven cities, KIYATEC raised almost $700K with AIM Group. While we see this investment as one of the more risky in our portfolio, we believe the upside will be huge.